Alkermes efforts to create its own line of wholly-owned products beyond its side business as a formulation expert have not been the most successful so far. In fact, data released Jan. 21 could sideline one of its most promising efforts.
The biotech announced results from closely-watched Phase III trials of major depressive disorder therapy ALKS-5461. Both the FORWARD-3 trial and...